|
SPCS2 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.7098544802252E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.59919855136081E-11 |
| Normal-vs-Stage2 |
1.167490E-04 |
| Normal-vs-Stage3 |
4.88498130835069E-15 |
| Normal-vs-Stage4 |
1.63469238145808E-12 |
| Stage1-vs-Stage2 |
2.088800E-01 |
| Stage1-vs-Stage3 |
1.635120E-03 |
| Stage1-vs-Stage4 |
2.12279999999287E-05 |
| Stage2-vs-Stage3 |
2.103000E-03 |
| Stage2-vs-Stage4 |
1.445640E-04 |
| Stage3-vs-Stage4 |
9.067700E-02 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
<1E-12 |
| Normal-vs-AfricanAmerican |
1.408160E-04 |
| Normal-vs-Asian |
6.78039846491174E-11 |
| Caucasian-vs-AfricanAmerican |
9.802200E-01 |
| Caucasian-vs-Asian |
3.635400E-01 |
| AfricanAmerican-vs-Asian |
7.334200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.3621326289126E-12 |
| Normal-vs-Female |
2.86937140714372E-12 |
| Male-vs-Female |
3.019400E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.34879885038686E-11 |
| Normal-vs-Age(41-60Yrs) |
2.27200480651391E-11 |
| Normal-vs-Age(61-80Yrs) |
1.61100022211258E-11 |
| Normal-vs-Age(81-100Yrs) |
3.69970000000386E-05 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
5.096600E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
1.003620E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
3.251600E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
2.998200E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
5.014800E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
7.875200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
2.31700003627822E-09 |
| Classical-VS-Follicular |
1.23029999965496E-07 |
| Classical-VS-Other |
8.597800E-01 |
| Classical-VS-Normal |
1.62447832963153E-12 |
| Tall-VS-Follicular |
1.62525548574877E-12 |
| Tall-VS-Other |
1.196050E-03 |
| Tall-VS-Normal |
1.62447832963153E-12 |
| Follicular-VS-Other |
1.175010E-01 |
| Follicular-VS-Normal |
1.738350E-02 |
| Other-VS-Normal |
5.633000E-04 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.77269998680174E-09 |
| Normal-vs-N1 |
5.19584375524573E-14 |
| N0-vs-N1 |
6.627700E-04 |
|
|
